Breaking News Instant updates and real-time market news.

BCRX

BioCryst

$8.81

-0.08 (-0.90%)

17:28
01/11/19
01/11
17:28
01/11/19
17:28

Great Point Partners reports 6.95% passive stake in BioCryst

In a regulatory filing, Great Point Partners disclosed a 6.95% stake in BioCryst, which reprsents about 7.6M shares. The filing does not allow for activism.

BCRX BioCryst
$8.81

-0.08 (-0.90%)

12/04/18
RBCM
12/04/18
NO CHANGE
Target $16
RBCM
Outperform
BioCryst price target raised to $16 from $10 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on BioCryst to $16 and kept his Outperform rating, saying that in spite of the 30% stock price appreciation over the past two weeks, investors continue to undervalue the future opportunity and the likelihood of success of its lead drug BCX7353. The analyst is positive on the drug's potential in both Hereditary Angioedemas prophylaxis and in on-demand treatment, anticipating a "good probability of success" for its Phase 3 APEX-2 results anticipated in Q2 of next year. Abrahams believes that the on-demand setting of BCX7353 could yield nearly $200M in potential out-year revenues.
11/16/18
PIPR
11/16/18
INITIATION
Target $15
PIPR
Overweight
BioCryst resumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren resumed coverage of BioCryst Pharmaceuticals with an Overweight rating and $15 price target. The company has two potential $500M-plus oral drugs, both for the prophylaxis and the acute treatment of hereditary angioedema. The analyst believes both will likely be successfully developed and finds the stock undervalued at current levels.
10/15/18
STFL
10/15/18
INITIATION
Target $33
STFL
Buy
KalVista initiated with a Buy at Stifel
Stifel analyst Paul Matteis started KalVista Pharmaceuticals (KALV) with a Buy rating and $33 price target. The company's lead asset KVD900, an oral plasma kallikrein inhibitor, has a "realistic shot" at being a best-in-class acute therapy for hereditary angioedema, Matteis tells investors in a research note. He thinks clinical results from competitor BioCryst (BCRX) "corroborate the viability of the oral kallikrein inhibitor approach but simultaneously leave room for improvement."
09/05/18
JMPS
09/05/18
NO CHANGE
Target $16
JMPS
Outperform
BioCryst price target raised to $16 from $12 at JMP Securities
JMP Securities analyst Liisa Bayko raised her price target on BioCryst to $16 from $12 after data from the Phase 2 ZENITH-1 trial showed the liquid formulation of 750 mg BCX7353 was superior to placebo in multiple clinical outcomes measuring hereditary angioedema attacks. The data for BCX7353 opens the door to the acute treatment setting, Bayko tells investors. She maintains her Outperform rating on BioCryst shares.

TODAY'S FREE FLY STORIES

UQM

UQM Technologies

$1.10

0.05 (4.76%)

13:05
01/21/19
01/21
13:05
01/21/19
13:05
Hot Stocks
UQM Technologies acquired by Danfoss Power Solutions for $1.71 per share »

UQM Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$41.50

-0.54 (-1.28%)

12:37
01/21/19
01/21
12:37
01/21/19
12:37
Hot Stocks
Sanofi granted U.K. marketing authorization for TIV High Dose »

U.K. marketing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

RTN

Raytheon

$165.11

2.285 (1.40%)

12:33
01/21/19
01/21
12:33
01/21/19
12:33
Hot Stocks
Raytheon awarded $24.36M order for F/A-18 aircraft system repair »

Raytheon said it was a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBCP

Independent Bank

$22.80

-0.11 (-0.48%)

11:26
01/21/19
01/21
11:26
01/21/19
11:26
Hot Stocks
Independent Bank boosts quarterly dividend by 20% to 18c »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

11:25
01/21/19
01/21
11:25
01/21/19
11:25
General news
FX Update: The dollar majors have been directionally challenged »

FX Update: The dollar…

EDIT

Editas Medicine

$26.16

-0.01 (-0.04%)

11:25
01/21/19
01/21
11:25
01/21/19
11:25
Hot Stocks
Editas Medicine announces publication of EDIT-101 data in Nature Medicine »

Editas Medicine announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

, GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

11:23
01/21/19
01/21
11:23
01/21/19
11:23
Hot Stocks
France's National Data Protection Commission fines Google 50M euros »

France's National…

GOOG

Alphabet

$1,098.25

6.96 (0.64%)

GOOGL

Alphabet Class A

$1,106.92

7.52 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 04

    Feb

  • 04

    Feb

  • 25

    Feb

  • 03

    Mar

LAD

Lithia Motors

$87.13

1.57 (1.84%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
Lithia Motors to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

  • 13

    Feb

  • 14

    Mar

CYDY

CytoDyn

$0.00

(0.00%)

10:25
01/21/19
01/21
10:25
01/21/19
10:25
Conference/Events
CytoDyn participates in lunch meeting with Philadelphia Securities »

Luncheon Meeting with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jan

ABT

Abbott

$71.43

0.9 (1.28%)

09:50
01/21/19
01/21
09:50
01/21/19
09:50
Hot Stocks
Abbott announces FDA approval of TactiCath Contact Force Ablation Catheter »

Abbott announced FDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 27

    Jan

SFUN

Fang Holdings

$1.88

-0.01 (-0.53%)

09:48
01/21/19
01/21
09:48
01/21/19
09:48
Hot Stocks
Fang announces management changes, proposed China Index spin-off »

Fang Holdings announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TS

Tenaris

$24.32

0.64 (2.70%)

09:45
01/21/19
01/21
09:45
01/21/19
09:45
Hot Stocks
Tenaris closes acquisition of 47.79% of Saudi Steel Pipe shares »

Tenaris S.A. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAAS

Pan American Silver

$14.17

-0.31 (-2.14%)

09:42
01/21/19
01/21
09:42
01/21/19
09:42
Hot Stocks
Pan American reports 2018 silver production 24.8M ounces »

Pan American Silver Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRWS

Crown Crafts

$5.68

(0.00%)

09:38
01/21/19
01/21
09:38
01/21/19
09:38
Hot Stocks
Crown Crafts announces retirement of NoJo Baby & Kids CEO »

Crown Crafts (CRWS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AL

Air Lease

$37.50

0.6 (1.63%)

, BA

Boeing

$364.79

5.52 (1.54%)

09:36
01/21/19
01/21
09:36
01/21/19
09:36
Hot Stocks
Air Lease announces lease placement of Boeing 737 MAX 9 »

Air Lease (AL) announced…

AL

Air Lease

$37.50

0.6 (1.63%)

BA

Boeing

$364.79

5.52 (1.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 21

    Feb

  • 28

    May

UTSI

UTStarcom

$3.22

0.1 (3.21%)

09:34
01/21/19
01/21
09:34
01/21/19
09:34
Hot Stocks
UTStarcom says TDI paid $4.54 per share to increase stake to 9.9% »

UTStarcom announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRTX

Vertex

$194.63

4.19 (2.20%)

09:31
01/21/19
01/21
09:31
01/21/19
09:31
Hot Stocks
Vertex says European Commission granted label extension for Orkambi »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Feb

ALNY

Alnylam

$83.08

2.4 (2.97%)

09:30
01/21/19
01/21
09:30
01/21/19
09:30
Hot Stocks
Alnylam, Israel's Medison partner to commercialize Onpattro, RNAi portfolio »

Alnylam Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THO

Thor Industries

$66.56

1.905 (2.95%)

09:26
01/21/19
01/21
09:26
01/21/19
09:26
Hot Stocks
Thor finalizing talks to exclude EHG's North American operations from deal »

Thor Industries provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLWTY

Panalpina

$0.00

(0.00%)

08:44
01/21/19
01/21
08:44
01/21/19
08:44
Downgrade
Panalpina rating change at Jefferies »

Panalpina downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFGSY

Eiffage

$0.00

(0.00%)

08:41
01/21/19
01/21
08:41
01/21/19
08:41
Upgrade
Eiffage rating change at Barclays »

Eiffage upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TVFCF

Television Francaise 1

$0.00

(0.00%)

08:40
01/21/19
01/21
08:40
01/21/19
08:40
Downgrade
Television Francaise 1 rating change at Citi »

Television Francaise 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVDY

Atresmedia

$0.00

(0.00%)

08:37
01/21/19
01/21
08:37
01/21/19
08:37
Upgrade
Atresmedia rating change at Citi »

Atresmedia upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDPAY

Tod's

$0.00

(0.00%)

08:36
01/21/19
01/21
08:36
01/21/19
08:36
Downgrade
Tod's rating change at Citi »

Tod's downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFRGY

Salvatore Ferragamo

$0.00

(0.00%)

08:35
01/21/19
01/21
08:35
01/21/19
08:35
Downgrade
Salvatore Ferragamo rating change at Citi »

Salvatore Ferragamo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.